Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from vTv Therapeutics ( (VTVT) ) is now available.
On August 29, 2025, vTv Therapeutics Inc. announced a private placement agreement with institutional investors, involving the sale of 5,243,732 units comprising shares and warrants, expected to raise approximately $80 million. The company also entered into a registration rights agreement to facilitate the resale of these securities, with obligations to file a registration statement with the SEC and potential liquidated damages for non-compliance, impacting its financial strategy and investor relations.
The most recent analyst rating on (VTVT) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on vTv Therapeutics stock, see the VTVT Stock Forecast page.
Spark’s Take on VTVT Stock
According to Spark, TipRanks’ AI Analyst, VTVT is a Underperform.
vTv Therapeutics’ overall stock score reflects significant financial difficulties and a speculative valuation, balanced by positive developments in its clinical trials. While the corporate events suggest future potential, the current financial instability and lack of profitability weigh heavily on the stock’s attractiveness.
To see Spark’s full report on VTVT stock, click here.
More about vTv Therapeutics
vTv Therapeutics Inc. operates in the biotechnology industry, focusing on the development of orally administered small molecule drug candidates. The company is primarily engaged in the research and development of treatments for a range of diseases, with a particular emphasis on diabetes and Alzheimer’s disease.
Average Trading Volume: 4,703
Technical Sentiment Signal: Strong Sell
Current Market Cap: $49.6M
Find detailed analytics on VTVT stock on TipRanks’ Stock Analysis page.